About Pear Therapeutics
Pear Therapeutics is a company based in Boston (United States) founded in 2013 by William Greene, Stephen Kennedy Smith, Ian Mcfarland, and Corey McCann. It operates as a B2B. Pear Therapeutics has raised $266.34 million across 9 funding rounds from investors including Novartis, HHS and Temasek. The company has 207 employees as of December 31, 2022. Pear Therapeutics has completed 1 acquisition, including Firsthand Technology. Pear Therapeutics operates in a competitive market with competitors including DarioHealth, Welldoc, Wellthy Therapeutics, Spiras Health and Ciba Health, among others.
- Headquarter Boston, United States
- Employees 207 as on 31 Dec, 2022
- Founders William Greene, Stephen Kennedy Smith, Ian Mcfarland, Corey McCann
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
$12.7 M (USD)0as on Dec 31, 2022
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$266.34 M (USD)
in 9 rounds
-
Latest Funding Round
Not available
-
Investors
Novartis
& 14 more
-
Employee Count
207
as on Dec 31, 2022
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Pear Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Pear Therapeutics
Pear Therapeutics has successfully raised a total of $266.34M across 9 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Pear Therapeutics
Pear Therapeutics has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Novartis, HHS and Temasek.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments in technology and startups.
|
Locked | Locked | Locked | |
|
An investment platform is provided for diverse sectors and geographies.
|
Locked | Locked | Locked | |
|
Healthcare venture capital investments are made by Arboretum Ventures.
|
Locked | Locked | Locked |
Investor details for Pear Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Pear Therapeutics
Pear Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Firsthand Technology.
Investment portfolio details for Pear Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Virtual Reality Games, Simulations & Therapy
|
Locked | Locked | 1995 | Locked |
Complete acquisition details for Pear Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Pear Therapeutics
Detailed financials for Pear Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pear Therapeutics Comparisons
Peer comparison for Pear Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Pear Therapeutics
Pear Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as DarioHealth, Welldoc, Wellthy Therapeutics, Spiras Health and Ciba Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Chronic conditions are managed via a personalized digital platform.
|
|
| Locked | Locked | Locked |
Mobile health products for chronic disease management are offered.
|
|
| Locked | Locked | Locked |
Health monitoring app is provided for chronic patients and providers.
|
|
| Locked | Locked | Locked |
Asthma and COPD symptoms are managed through clinical services.
|
|
| Locked | Locked | Locked |
Provider of teleconsultation and digital therapeutic software for employees and patients
|
Detailed competitors of Pear Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pear Therapeutics
Complete news archive for Pear Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pear Therapeutics
Pear Therapeutics was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Pear Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Corey McCann is the current CEO of Pear Therapeutics. They have also founded this company.
Pear Therapeutics is a funded company, having raised a total of $266.34M across 9 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Pear Therapeutics is 207.
Annual revenue of Pear Therapeutics is $12.7M as on Dec 31, 2022.
Pear Therapeutics operates with a B2B model, focusing on providing healthcare solutions, providing digital health services, therapeutics, and chronic disease management. Pear Therapeutics provides cloud-based digital solutions for managing chronic health conditions effectively. It emphasizes efficiency, client-focused solutions, and growth, fostering partnerships and innovation in its operations.
Pear Therapeutics's top competitors include Welldoc, Wellthy Therapeutics and DarioHealth.
Pear Therapeutics has made 1 acquisition, including Firsthand Technology.
Pear Therapeutics has 15 investors. Key investors include Novartis, HHS, Temasek, SoftBank Vision Fund, and Perceptive Advisors.